PACSPACS Group, Inc.
Is the price fair?
Undemanding: modest expectations priced in and cheap vs its sector.
Priced for ~1% a year FCF growth. The price bakes in little to no growth.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What PACS's price assumes
PACS Group, Inc. trades at 25.3× earnings against 20.0× for the median Medical Care Facilities name, more expensive than its own group.
Trailing P/E · Medical Care Facilities median 20.0 · 1.27× the median: the market pays up for this one
- Price / sales
- 1.16
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 7.1%
Free cash flow yield · Medical Care Facilities median 7.1%
- Growth the price implies
- +1.0%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 5.80
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 15.9
- EV / salestoday's price, trailing year to Jun 30, 2026
- 1.17
- Healthcare median P/E509 names
- 26.2
- Medical Care Facilities median P/E33 names
- 20.0
- Free cash flow, trailing twelve months
- $456M
- Market capitalisation
- $6.44B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.